Table 2.
Breast cancer–specific survival in NF1 and screened non-NF1 group after the first breast cancer
| Follow-up from breast cancer | Delayed entry | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cohort | Time since breast cancer (years) | n At risk | n Eventsa | Survival (95% CI) | HR (95% CI) | n At risk | n Eventsa | Survival (95% CI) | HR (95% CI) |
| Non-NF1, Manchester Family History Clinic | 0 | 335 | 0 | 1.000 (1.000 to 1.000) | Ref. | 334 | 0 | 1.000 (1.000 to 1.000) | Ref. |
| 5 | 177 | 13 | 0.940 (0.909 to 0.972) | 177 | 13 | 0.940 (0.909 to 0.972) | |||
| 10 | 105 | 5 | 0.912 (0.873 to 0.952) | 105 | 5 | 0.912 (0.873 to 0.952) | |||
| 20 | 19 | 2 | 0.893 (0.849 to 0.941) | 19 | 2 | 0.893 (0.849 to 0.941) | |||
| 30 | 0 | 0 | 0.893 (0.849 to 0.941) | 0 | 0 | 0.893 (0.849 to 0.941) | |||
| All NF1 | 0 | 142 | 0 | 1.000 (1.000 to 1.000) | 2.7 (1.5 to 4.8) | 96 | 0 | 1.000 (1.000 to 1.000) | 3.6 (2.0 to 6.5) |
| 5 | 81 | 20 | 0.833 (0.768 to 0.903) | 57 | 19 | 0.782 (0.699 to 0.874) | |||
| 10 | 47 | 5 | 0.776 (0.700 to 0.859) | 32 | 5 | 0.709 (0.615 to 0.817) | |||
| 20 | 15 | 1 | 0.754 (0.671 to 0.847) | 12 | 1 | 0.680 (0.578 to 0.801) | |||
| 30 | 2 | 0 | 0.754 (0.671 to 0.847) | 1 | 0 | 0.680 (0.578 to 0.801) | |||
| NF1 excluding Padova | 0 | 115 | 0 | 1.000 (1.000 to 1.000) | 3.3 (1.8 to 5.9) | 74 | 0 | 1.000 (1.000 to 1.000) | 4.6 (2.5 to 8.3) |
| 5 | 64 | 20 | 0.796 (0.720 to 0.881) | 43 | 19 | 0.729 (0.631 to 0.842) | |||
| 10 | 37 | 5 | 0.728 (0.640 to 0.828) | 25 | 5 | 0.642 (0.535 to 0.770) | |||
| 20 | 13 | 1 | 0.704 (0.609 to 0.813) | 11 | 1 | 0.611 (0.498 to 0.751) | |||
| 30 | 1 | 0 | 0.704 (0.609 to 0.813) | 1 | 0 | 0.611 (0.498 to 0.751) | |||
| NF1, Finland | 0 | 47 | 0 | 1.000 (1.000 to 1.000) | 3.2 (1.5 to 6.7) | 32 | 0 | 1.000 (1.000 to 1.000) | 4.1 (1.9 to 8.7) |
| 5 | 29 | 10 | 0.767 (0.650 to 0.906) | 22 | 9 | 0.711 (0.568 to 0.890) | |||
| 10 | 17 | 1 | 0.739 (0.616 to 0.886) | 12 | 1 | 0.677 (0.531 to 0.864) | |||
| 20 | 7 | 0 | 0.739 (0.616 to 0.886) | 5 | 0 | 0.677 (0.531 to 0.864) | |||
| 30 | 1 | 0 | 0.739 (0.616 to 0.886) | 1 | 0 | 0.677 (0.531 to 0.864) | |||
| NF1, Manchester | 0 | 33 | 0 | 1.000 (1.000 to 1.000) | 7.3 (3.5 to 15.3) | 19 | 0 | 1.000 (1.000 to 1.000) | 13.6 (6.4 to 28.9) |
| 5 | 10 | 7 | 0.700 (0.531 to 0.923) | 3 | 7 | 0.530 (0.313 to 0.897) | |||
| 10 | 6 | 3 | 0.490 (0.300 to 0.801) | 4 | 3 | 0.236 (0.078 to 0.716) | |||
| 20 | 2 | 1 | 0.392 (0.203 to 0.757) | 2 | 1 | 0.157 (0.040 to 0.618) | |||
| 30 | 0 | 0 | 0.392 (0.203 to 0.757) | 0 | 0 | 0.157 (0.040 to 0.618) | |||
| NF1, Hamburg | 0 | 15 | 0 | 1.000 (1.000 to 1.000) | 2.4 (0.7 to 8.0) | 15 | 0 | 1.000 (1.000 to 1.000) | 2.4 (0.7 to 8.0) |
| 5 | 11 | 2 | 0.867 (0.711 to 1.000) | 11 | 2 | 0.867 (0.711 to 1.000) | |||
| 10 | 7 | 1 | 0.788 (0.600 to 1.000) | 7 | 1 | 0.788 (0.600 to 1.000) | |||
| 20 | 2 | 0 | 0.788 (0.600 to 1.000) | 2 | 0 | 0.788 (0.600 to 1.000) | |||
| 30 | 0 | 0 | 0.788 (0.600 to 1.000) | 0 | 0 | 0.788 (0.600 to 1.000) | |||
| NF1, Padova | 0 | 27 | 0 | 1.000 (1.000 to 1.000) | Not available (no events) | 22 | 0 | 1.000 (1.000 to 1.000) | Not available (no events) |
| 5 | 17 | 0 | 1.000 (1.000 to 1.000) | 14 | 0 | 1.000 (1.000 to 1.000) | |||
| 10 | 10 | 0 | 1.000 (1.000 to 1.000) | 7 | 0 | 1.000 (1.000 to 1.000) | |||
| 20 | 2 | 0 | 1.000 (1.000 to 1.000) | 1 | 0 | 1.000 (1.000 to 1.000) | |||
| 30 | 1 | 0 | 1.000 (1.000 to 1.000) | 0 | 0 | 1.000 (1.000 to 1.000) | |||
| NF1, Paris | 0 | 20 | 0 | 1.000 (1.000 to 1.000) | 0.6 (0.1 to 4.6) | 8 | 0 | 1.000 (1.000 to 1.000) | 1.1 (0.2 to 8.5) |
| 5 | 14 | 1 | 0.933 (0.815 to 1.000) | 7 | 1 | 0.857 (0.633 to 1.000) | |||
| 10 | 7 | 0 | 0.933 (0.815 to 1.000) | 2 | 0 | 0.857 (0.633 to 1.000) | |||
| 20 | 2 | 0 | 0.933 (0.815 to 1.000) | 2 | 0 | 0.857 (0.633 to 1.000) | |||
| 30 | 0 | 0 | 0.933 (0.815 to 1.000) | 0 | 0 | 0.857 (0.633 to 1.000) | |||
CI confidence interval,HR hazard ratio, NF1 neurofibromatosis 1.
aDescribes the number of breast cancer deaths since the previous time point.